Autologous Bone Marrow Transplantation: A Review

References

• Frei E III, Canellos GP: Dose: a critical factor in cancer chemotherapy. Am J Med 69: 585–594, 1980.
   PubMed Web of Science ®Google Scholar
• Thomas E, Storb R, Clift RA, et al: Bone marrow transplantation. N Engl J Med 292: 832–843, 1975.
   PubMed Web of Science ®Google Scholar
• Ashwood-Smith MJ, Farrant J, eds: Low Temperature Preservation in Medicine and Biology. Baltimore, University Park Press, 1980.
   Google Scholar
• Herzig GP: Autologous marrow transplantation in cancer therapy. In Brown EB, ed: Progress in Hematology, vol 12. New York, Grune and Stratton, 1981, pp 1–23.
   Google Scholar
• Dicke KA, McCredie KB, Stevens EE, et al: Autologous bone marrow transplantation in a case of acute adult leukemia. Transplant Proc 9: 193–195, 1977.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Herzig G, Graw RG, et al: Accelerated hemopoietic recovery following the infusion of cryopreserved autologous bone marrow in humans. Exp Hematol 7: 297–301, 1979.
   PubMed Web of Science ®Google Scholar
• Fay JW, Silberman HR, Moore JO, et al: Autologous marrow transplantation for patients with acute myelogenous leukemia—a preliminary report. Exp Hematol 7: 302, 1979.
   Web of Science ®Google Scholar
• Phillips GL, Herzig RH, Lazarus HM, et al: Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow. N Engl J Med 310: 1557–1561, 1984.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Lacerna L, Jones-Leyland B, et al: Autologous bone marrow transplantation: current status and future directions. Ann Intern Med 110: 51–65, 1989.
   PubMed Web of Science ®Google Scholar
• Frei E III, Antman K, Teicher B, et al: Bone marrow autotransplantation for solid tumors—prospects. J Clin Oncol 7: 515–526, 1989.
   PubMed Web of Science ®Google Scholar
• Herzig GP, Herzig R: Current concepts in dose intensity and marrow transplantation. In Gale RP, ed: Acute Myelogenous Leukemia: Progress and Controversies. New York, Wiley-Liss, 1990, pp 333–344.
   Google Scholar
• Herzig RH, Fay JW, Herzig GP, et al: Phase I–II studies with high-dose thiotepa and autologous marrow transplantation in patients with refractory malignancies. In: Advances in Cancer Chemotherapy: High Dose Thiotepa and Autologous Marrow Transplantation (symposium proceedings). Oxford, England, John Wiley and Sons, 1987, pp 17–23.
   Google Scholar
• Chabner BA: Clinical strategies for cancer treatment: the role of drugs. In Chabner BA, Collins JM, eds: Cancer Chemotherapy: Principles and Practice. Philadelphia, JB Lippincott Company, 1990, pp 1–15.
   Google Scholar
• Teicher BA, Cucchi CA, Lee JB, et al: Alkylating agents: in vitro studies of cross-resistance patterns in human tumor cell lines. Cancer Res 46: 4379–4383, 1986.
   PubMed Web of Science ®Google Scholar
• Santos GW, Tutschka PJ, Brookmeyer R, et al: Marrow transplantation for acute non-lymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309: 1347–1353, 1983.
   PubMed Web of Science ®Google Scholar
• Brown RA, Herzig RH, Wolff SN, et al: High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 76: 473–479, 1990.
   PubMed Web of Science ®Google Scholar
• Fay JW, Wolff S, Herzig R, et al: Treatment of non-Hodgkin's lymphoma with intensive VP-16, cyclophosphamide, total body radiotherapy, and autologous marrow transplantation. (Abstr) Proceedings of the American Society of Clinical Oncology 9: 260a, 1990.
   Google Scholar
• Phillips GL, Wolff SN, Herzig RH, et al: Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 73: 2086–2092, 1989.
   PubMed Web of Science ®Google Scholar
• Fay JW, Collins RH, Herzig R, et al: Intensive thiotepa, cyclophosphamide, and autologous marrow transplantation for breast cancer and malignant melanoma. (Abstr) The Fifth International Symposium on Autologous Bone Marrow Transplantation, 218a, 1990.
   Google Scholar
• Champlin RE, Gale RP: The early complications of bone marrow transplantation. Semin Hematol 21: 101–108, 1984.
   PubMed Web of Science ®Google Scholar
• Freedman AS, Takvorian T, Anderson KC, et al: Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 8: 784–791, 1990.
   PubMed Web of Science ®Google Scholar
• Kessinger A, Nademanee A, Forman S, et al: Autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 4: 577–587, 1990.
   Web of Science ®Google Scholar
• Phillips GL, Fay JW, Herzig RH, et al: The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood 75: 831–838, 1990.
   PubMed Web of Science ®Google Scholar
• Yeager AM, Kaizer H, Santos GW, et al: Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 315: 141–147, 1986.
   PubMed Web of Science ®Google Scholar
• Gorin NC, Aegerter P, Auvert B, et al: Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 75: 1606–1614, 1990.
   PubMed Web of Science ®Google Scholar
• Gale RP, Butturini AM: Autotransplants in leukaemia. Lancet 2: 315–317, 1989.
   PubMed Web of Science ®Google Scholar
• Ihde DC, Deisseroth AB, Lichter AS, et al: Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. J Clin Oncol 4: 1443–1454, 1986.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Dicke K, et al: Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood 76: 1860–1866, 1990.
   PubMed Web of Science ®Google Scholar
• Graham-Pole J: The role of marrow autografting in neuroblastoma (editorial). Bone Marrow Transplant 4: 3, 1989.
   Google Scholar
• Antman K, Gale RP: Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants. Ann Intern Med 108: 570–574, 1988.
   PubMed Web of Science ®Google Scholar
• Peters WP, Shpall EJ, Jones RB, et al: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6: 1368–1376, 1988.
   PubMed Web of Science ®Google Scholar
• Peters WP, Jones R, Shpall EJ, et al: Use of high-dose combination alkylating agents in the treatment of metastatic breast cancer. (Abstr) The Fifth International Symposium on Autologous Bone Marrow Transplantation, 80a, 1990.
   Google Scholar
• Peters WP, Ross M, Vredenburgh I, et al: High-dose chemotherapy and autologous bone marrow support in the adjuvant treatment of primary breast cancer. (Abstr) The Fifth International Symposium on Autologous Bone Marrow Transplantation, 88a, 1990.
   Google Scholar
• Fay J, Herzig G, Collins RH, et al: Chemotherapy treated autologous marrow transplantation for non-Hodgkin's lymphoma. (Abstr) Blood 75: 538a, 1990.
   Web of Science ®Google Scholar
• Chang J, Coutinho L, Morgenstern G, et al: Reconstitution of haemopoietic system with autologous marrow taken during relapse of acute myeloblastic leukaemia and grown in long-term culture. Lancet 1: 294–295, 1986.
   PubMed Web of Science ®Google Scholar
• Barnett MJ, Eaves CJ, Phillips GL, et al: Autografting in chronic myeloid leukemia (CML) with cultured marrow: consistent restoration of Philadelphia chromosome (PH1)-negative hematopoiesis in patients selected by prior assessment of their marrow in vitro. Blood 76: 526a, 1990.
   Google Scholar
• Williams SF, Bitran JD, Richards JM, et al: Peripheral blood-derived stem cell collections for use in autologous transplantation after high-dose chemotherapy: an alternative approach. Bone Marrow Transplant 5: 129–133, 1990.
   PubMed Web of Science ®Google Scholar
• Jones RJ, Wagner JE, Celano P, et al: Separation of pluripotent hematopoietic stem cells from spleen colony-forming cells. Nature 347: 188–189, 1990.
   PubMed Web of Science ®Google Scholar
• Groopman JE, Molina JM, Scadden DT: Hematopoietic growth factors: biology and clinical applications. N Engl J Med 321: 1449–1459, 1989.
   PubMed Web of Science ®Google Scholar
• Mertelsmann R, Herrmann F, Hecht T, et al: Hematopoietic growth factors in bone marrow transplantation. Bone Marrow Transplant 6: 73–77, 1990.
   PubMed Web of Science ®Google Scholar
• Rabinowe S, Freedman A, Demetri G, et al: Randomized double blinded trial of rhGM-CSF in patients with B-cell non-Hodgkin's lymphoma (B-NHL) undergoing high-dose chemoradiotherapy and monoclonal antibody purged autologous bone marrow transplantation (ABMT). Blood 76: 161a, 1990.
   Google Scholar
• Peters WP, Kurtzberg I, Kirkpatrick G, et al: GM-CSF primed peripheral blood progenitor cells (PBPC) coupled with autologous bone marrow transplantation (ABMT) will eliminate absolute leukopenia following high-dose chemotherapy (HDC). (Abstr) Blood 74: 50a, 1989.
   Google Scholar
• Witte ON: Steel locus defines new multipotent growth factor. Cell 63: 5–6, 1990.
   PubMed Web of Science ®Google Scholar
• Endicott JA, Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137–171, 1989.
   PubMed Web of Science ®Google Scholar
• Dalton WS, Grogan TM, Meltzer PS, et al: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by additions of verapamil to chemotherapy. J Clin Oncol 7: 415–424, 1989.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Griffin JD: Hematopoietins and leukemia. Hematol Oncol Clin North Am 3: 535–553, 1989.
   Web of Science ®Google Scholar
• Press O, Eary J, Badger C, et al: Radioimmunotherapy (RIT) of refractory non-Hodgkin's lymphomas (NHL) with I-131-labeled pan-B monoclonal antibodies (mAB). (Abstr) Proceedings of the American Society of Clinical Oncology 8: 937a, 1989.
   Google Scholar
• Vitetta ES, Fulton RJ, May RD, et al: Redesigning nature's poisons to create antitumor reagents. Science 238: 1098–1104, 1987.
   PubMed Web of Science ®Google Scholar
• Stone M, Amlot P, Fay J, et al: Immunotoxin therapy of B-cell lymphoma. (Abstr) Blood 76: 374a, 1990.
   Web of Science ®Google Scholar
• Hess AD, Fischer AC: Immune mechanisms in cyclosporine-induced syngeneic graft-versus-host disease. Transplantation 48: 895–900, 1989.
   PubMed Web of Science ®Google Scholar
• Geller RB, Esa AH, Beschorner WE, et al: Successful in vitro graft-vs-tumor effect against an Ia-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 74: 1165–1171, 1989.
   PubMed Web of Science ®Google Scholar
• Jones RJ, Vogelsang GB, Hess AD, et al: Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1: 754–757, 1989.
   PubMed Web of Science ®Google Scholar
• van Haelst-Pisani CM, Pisani RJ, Kovach JS: Cancer immunotherapy: current status of treatment with interleukin 2 and lymphokine-activated killer cells. Mayo Clin Proc 64: 451–465, 1989.
   PubMed Web of Science ®Google Scholar
• Topalin SL, Rosenberg SA: Tumor-infiltrating lymphocytes: evidence for specific immune reactions against growing cancers in mice and humans. In DeVita VT, Hellman S, Rosenberg SA, eds: Important Advances in Oncology 1990. Philadelphia, JB Lippincott Company, 1990, pp 19–41.
   Google Scholar